Sep 30 2026

george

September 2026 QQ Summary: Anticoagulant Therapy for LAC Patients with VTE

Our September 2026 QQ asked: In your facility, what AC do you use for LAC patients with VTE? Our 13 respondents answered: Anti-Xa DOAC: 5 (39%) Warfarin: 8 (61%) No one chose an anti-IIa DOAC, aspirin, or “none.” There have been provocative discussions among KOL experts comparing the long-term use of warfarin (VKA) v. anti-Xa […]

read more

Comments (0)

Thrombophilia

Sep 30 2026

george

A Summary of VWD Management by Dr. Favaloro

See this open-access editorial summarizing current VWD diagnosis and management. Favaloro EJ. 100 years of von Willebrand disease: celebrating a significant milestone in von Willebrand disease diagnostics and management. Semin Thromb Hemost. 2026;52(7):762-764. doi: 10.1055/a-2877-9583. PMID: 42190737. Further, here’s a link to the entire Seminars in Thrombosis and Hemostasis, October 2026, that addresses Hemostasis in […]

read more

Comments (0)

Bleeding Disorders

Sep 28 2026

george

Review: Pediatric VTE

While we focus on arterial and venous thrombosis, October 13 is the official World Thrombosis Day. With this thought in mind, here is a richly illustrated review describing pediatric VTE: Espanol MG, Janbain M. Pediatric venous thromboembolism: an illustrated review. Res Pract Thromb Haemost. 2026;10:106892. doi: 10.1016/j.rpth.2026.106892. PMID: 42699084; PMCID: PMC13543900. Abstract Venous thromboembolism (VTE) […]

read more

Comments (0)

Thrombophilia

Sep 16 2026

george

Heparin Re-exposure in HIT Patients

Obtain this article about HIT from your local medical library: Caudill EB, Kim JH, Kanaan DM, Sylvester KW, Pimentel LY, Kim CS, Connors JM. Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia. J Thromb Haemost. 2026 Aug 3:S1538-7836(26)00484-8. doi: 10.1016/j.jtha.2026.07.024. PMID: 42546848. Objective To evaluate heparin re-exposure practices and safety in patients with […]

read more

Comments (0)

Anticoagulant Therapy

Sep 16 2026

george

Women and Girls With Hemophilia and Hemophilia Carriers

This open-access article details ISTH guidance in managing hemophilia in women and girls: Srivaths L, Ardila J, Fijnvandraat K, van Galen K, James P, Larson J, Shapiro S, Sidonio R, Escobar M. The diagnosis and evaluation of women and girls with hemophilia and hemophilia carriers: guidance from the SSC of the ISTH. J Thromb Haemost. […]

read more

Comments (0)

Bleeding Disorders

Sep 8 2026

george

Can AI Replace Clinical Prediction Scores in Thrombophilia?

Here is an open-access that compares the efficacy of AI with traditional clinical prediction scores for thrombophilia: Danilatou V, Arachchillage DJ. Beyond accuracy: why replacing traditional scores with AI in thrombosis care creates new ethical and regulatory obligations. Semin Thromb Hemost. 2026 Sep 3. doi: 10.1055/a-2943-7750. PMID: 42692078. Abstract Clinical prediction scores have been central […]

read more

Comments (0)

Thrombophilia

Sep 8 2026

george

Study Results: Novel Thrombin Generation Assay Monitors Emicizumab and Octocog Alfa

Here are the open-access results of a study testing the efficacy of a novel intrinsic trigger reagent (platelet-poor plasma [PPP] Reagent INT) for monitoring emicizumab and octocog alfa: Urlings EH, Heubel-Moenen FCJI, van Oerle R, et al. Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A. […]

read more

Comments (0)

Bleeding Disorders

Sep 4 2026

george

A Haematologica Review of all Hemophilia Rebalancing Therapy Efforts

Here is an open-access article describing all efforts to develop effective rebalancing therapy, including Latarcibart®, a MOAB that suppresses PS, not previously described in FF:  Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica. 2025 Dec 1;110(12):2902-2912. doi: 10.3324/haematol.2025.288245. PMID: 40820726; PMCID: PMC12666285. Abstract Treatment options for patients with hemophilia […]

read more

Comments (0)

Bleeding Disorders

Sep 4 2026

george

Monitoring ADAMTS13 Deficiency: An Expert Rev. Hematology Review

Here is a current open-access article about ADAMTS13 deficiency: Binder NB, Depasse F, Spannagl M, et al. Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach. Expert Rev Hematol. 2026 Sep;19(9):1037-1057. doi: 10.1080/17474086.2026.2702550. PMID: 42461718. Abstract Introduction: ADAMTS13, a crucial enzyme in hemostasis that specifically cleaves von Willebrand factor […]

read more

Comments (0)

Bleeding Disorders

Sep 3 2026

george

Addendum to QQ September 2026: Dr. Favaloro’s Reference

The article cited by Dr. Favaloro in his comment appended to the September 2026 QQ introduction is open access. Click here for the complete text: Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost. 2022;6:e12676. doi: 10.1002/rth2.12676. PMID: 35316943; PMCID: PMC8922544. Abstract Background Lupus anticoagulants (LA) are […]

read more

Comments (0)

Blog